Global Human Hepatitis B Immunoglobulin HBIG Market Size By Type (100IU/Bottle Human Hepatitis B Immunoglobulin, 200IU/Bottle Human Hepatitis B Immunoglobulin), By Application (Positive Infants Born t...

The Global Human Hepatitis B Immunoglobulin (HBIG) Market was valued at USD 1.1 billion in 2023 and is projected to surpass USD 2.3 billion by 2031, growing at a CAGR of 9.7% during the forecast period of 2023–2031. The rising global prevalence of hepatitis B, especially in regions with low vaccination coverage and high perinatal transmission rates, is significantly driving demand for HBIG. This immunoglobulin is a vital prophylactic treatment used to prevent hepatitis B virus (HBV) infection in individuals exposed to the virus, especially newborns of HBV-positive mothers, post-liver transplant recipients, and healthcare workers.

Drivers:

Increasing HBV Infection Rates and Global Disease Burden:

The continued global burden of hepatitis B, particularly in Asia-Pacific and Sub-Saharan Africa, is one of the main drivers for HBIG. As of 2023, over 296 million people are chronically infected with HBV globally, which fuels the demand for immediate post-exposure prophylaxis.

Expanded Use in Perinatal Care and Organ Transplants:

HBIG plays a critical role in neonatal prophylaxis, especially for infants born to HBV-infected mothers. Additionally, it is used in liver transplant recipients to prevent HBV recurrence, thereby increasing its clinical applications.

Government Initiatives and Vaccination Gaps:

Governments and health organizations, including the WHO, are actively working to eliminate HBV, and HBIG is a key element in high-risk population strategies. Its role is especially crucial in areas where vaccination rates are insufficient or delayed.

Restraints:

High Cost and Limited Accessibility:

The production of HBIG involves human plasma, making it an expensive biological product. Limited access in low-income countries due to high cost remains a major barrier to market penetration.

Dependence on Plasma Donations:

HBIG manufacturing is reliant on a stable and safe plasma supply, which is subject to regulatory scrutiny and donor availability. This dependence creates supply-chain constraints.

Opportunity:

Technological Advancements in Plasma Fractionation:

Emerging technologies in plasma processing and purification are expected to improve HBIG production yields, enhance product safety, and reduce production costs, paving the way for wider accessibility.

Market Expansion in Emerging Economies:

With hepatitis B being endemic in parts of Asia and Africa, expanding HBIG distribution in these regions offers a lucrative opportunity. Growing awareness and government health investments are encouraging trends in these markets.

Market by System Type Insights:

Based on formulation type, the intramuscular HBIG segment held the largest market share in 2023 due to its widespread use in post-exposure prophylaxis. However, the intravenous HBIG segment is projected to grow rapidly during the forecast period, primarily driven by increasing liver transplantation procedures and preference for hospital-based administration with controlled dosages.

Market by End-use Insights:

Hospitals were the largest end-use segment in 2023, accounting for over 60% of the market revenue. This is attributed to the administration of HBIG in critical scenarios like organ transplantation, post-exposure prophylaxis in medical settings, and neonatal care. Blood banks and specialty clinics are emerging as important distribution channels for preventive and emergency use.

Market by Regional Insights:

North America led the global HBIG market in 2023, driven by advanced healthcare systems, high diagnosis rates, and substantial organ transplant activity. Asia-Pacific is expected to witness the highest CAGR during the forecast period, supported by high HBV prevalence, growing government healthcare spending, and increasing awareness of HBIG therapy. Europe holds a mature market due to established screening and immunization protocols.

Competitive Scenario:

Key players in the Global Human Hepatitis B Immunoglobulin Market include CSL Behring, Grifols S.A., Kedrion Biopharma Inc., Biotest AG, Shire (now part of Takeda Pharmaceutical), Emergent BioSolutions Inc., Octapharma AG, Bharat Serums and Vaccines Limited, and Green Cross Corporation. These companies are focused on expanding plasma collection networks, developing next-generation immunoglobulin products, and strengthening distribution in high-burden regions.

Scope of Work – Global Human Hepatitis B Immunoglobulin (HBIG) Market

Key Market Developments:

2023: CSL Behring expanded its plasma collection centers globally, improving HBIG production capacity and distribution to underserved markets.

2024: Grifols launched an advanced formulation of intravenous HBIG with improved bioavailability and reduced administration time.

2025: Kedrion Biopharma announced a partnership with a public health agency in Southeast Asia to expand HBIG access for neonatal care.

FAQs:

What is the current market size of the Global Human Hepatitis B Immunoglobulin (HBIG) Market?

The market was valued at USD 1.1 billion in 2023.

What is the major growth driver of the Global Human Hepatitis B Immunoglobulin (HBIG) Market?

The major driver is the rising global burden of HBV infections and the need for effective post-exposure prophylaxis.

Which is the largest region during the forecast period in the Global Human Hepatitis B Immunoglobulin (HBIG) Market?

North America currently leads, while Asia-Pacific is expected to register the highest growth.

Which segment accounted for the largest market share in the Global Human Hepatitis B Immunoglobulin (HBIG) Market?

The intramuscular HBIG segment accounted for the largest share in 2023.

Who are the key market players in the Global Human Hepatitis B Immunoglobulin (HBIG) Market?

Key players include CSL Behring, Grifols S.A., Kedrion Biopharma, Biotest AG, and Octapharma AG.